Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2014

View Archived Issues

Shire's candidate for dystrophic epidermolysis bullosa receives FDA orphan drug status

FDA grants orphan drug status to ovarian cancer and CLL treatments

miRNA levels associated with response to cisplatin in metastatic bladder cancer patients

Medimetriks Pharmaceuticals licenses ozenoxacin from Ferrer

GSK seeks Japanese approval of clindamycin/benzoyl peroxide gel for acne

Vertical Pharmaceuticals acquires Upsher-Smith women's health products

NeuroVive and A1M Pharma to collaborate on mitochondrial medicine research

Spark Therapeutics and Genable collaborate on GT-038 for RHO adRP

Cellular Biomedicine reports results from phase I study of TC-DC for liver cancer

Kamada advances development of inhaled AAT therapy for AATD

GNAS gene mutations identified in spectrum of pancreatic carcinomas

Kaketsuken announces Japanese approval of cell culture pandemic influenza vaccine

Tofogliflozin hydrate approved for type 2 diabetes in Japan

Russia approves simeprevir for chronic hepatitis C genotype 1 infection

Results presented for the novel xanthine oxidase inhibitor LC-350189 in humans

Exelixis receives E.U. approval for Cometriq for medullary thyroid carcinoma

Gilead presents in vivo results for GS-9973

The University of Exeter presents new photodynamic agents for cancer

Rockwell Medical seeks FDA approval of Triferic

Novel SUMO-1 activators presented for heart failure and other disorders

Samsca approved in Japan for autosomal dominant polycystic kidney disease

Alectos Therapeutics and Merck & Co. patent novel glycosidase inhibitors

DMC recommends continuation of pivotal study of Firdapse for LEMS

Epilepsy Awareness Day: Personalized therapy options for early-onset epileptic encephalopathy

Nippon Shinyaku divulges novel mGlu5 receptor antagonists

Ariad begins phase II trial of AP-26113 for ALK+ refractory NSCLC

Japanese approval obtained for Sandoz's biosimilar filgrastim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...